doi: 10.1053/j.jrn.2015.02.006
Current clinical treatments, such as levodopa preparations, dopamine agonists, and catechol-O-methyltransferase (COMT) inhibitors, primarily focus on symptom management and provide only temporary relief of motor symptoms (Hglinger and Trenkwalder 2024)
Variable protein expression in platelets found evidence that the delE155 enzyme is present in platelets obtained from subjects that are heterozygous for the GSTO1delE155, K208 allele E210A O43708, Q9H4Y5, Q16772, P09211, P09210, P08263, P09488, O15217, P28161, Q03013, P46439, P78417, O60760, Q7RTV2, P21266, P0CG30 naturally occuring polymorphism F83A - site-directed mutagenesis, H-site mutation, the mutant shows increased activity compared to the wild-type enzyme F83W - site-directed mutagenesis, H-site mutation, the mutant shows increased activity compared to the wild-type enzyme F87A - site-directed mutagenesis, H-site mutation, the mutant shows increased activity compared to the wild-type enzyme F87W - site-directed mutagenesis, H-site mutation, the mutant shows increased activity compared to the wild-type enzyme G112C - mutant displays as high catalytic activity as wild type GST M1-1 G147W O43708, Q9H4Y5, Q16772, P09211, P09210, P08263, P09488, O15217, P28161, Q03013, P46439, P78417, O60760, Q7RTV2, P21266, P0CG30 the natural polymorphism occurs in a rare variant in Chinese individual G147W/V224I O43708, Q9H4Y5, Q16772, P09211, P09210, P08263, P09488, O15217, P28161, Q03013, P46439, P78417, O60760, Q7RTV2, P21266, P0CG30 site-directed mutagenesis, the double mutation results in a gain of function with a three fold increase in the specific activity with 1-chloro-2,4-dinitrobenzene as a substrate
However, this protection against aging has many risks
PMID 11821065
Q J Exp Physiol
